Regulated cell death (RCD) is an evolutionarily conserved process in multicellular organisms that is essential for organ development and tissue homeostasis maintenance. RCD also widely participates in the progression and development of human diseases. Cancer and neurodegenerative diseases are two extensively studied human diseases in RCD-related therapies and mechanisms and provide new thoughts to other diseases. Notably, the prevention of RCD is urgent to the nerve tissues because the regeneration of nerve tissues and their functions are very hard. Several key types of RCD have been identified based on distinct cell death signaling pathways, such as apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis, in recent decades. Individually or in combination, these new types of RCD individually contribute to various pathological processes.
In this regard, the ability to target RCD is a viable approach for developing therapeutic strategies (including pharmaceutical discovery and stem cell-based therapy) for treating cancer and neurodegenerative diseases. For example, autophagy inhibitors such as inhibitors of 3-methyl-adenine or chloroquine were used in combination with anticancer drugs to suppress tumor cell survival by inhibiting autophagy. Drugs and compounds designed to promote RCD, on the other hand, have shown promising therapeutic effects. Shikonin, a Chinese herbal medicine, for example, has been applied to treat primary and metastatic osteosarcomas by inducing RIPK1/3-dependent necroptosis.
We welcome submissions as Original Research and Review articles focus on the development of novel strategies to target cell death signaling in human disease and the investigation of the underlying mechanisms. This Research Topic may include, but is not limited to, the subtopics listed below:
• Development of drugs, compounds, and stem cell-based therapy for targeting RCD;
• Regulatory mechanisms of drugs, compounds, and stem cell-based therapy in targeting RCD;
• Drug resistance related to RCD in cancer;
• Side effects in RCD-related targeted therapies;
• Discovery of new types or mechanisms of RCD in cancer and neurodegenerative diseases.
Regulated cell death (RCD) is an evolutionarily conserved process in multicellular organisms that is essential for organ development and tissue homeostasis maintenance. RCD also widely participates in the progression and development of human diseases. Cancer and neurodegenerative diseases are two extensively studied human diseases in RCD-related therapies and mechanisms and provide new thoughts to other diseases. Notably, the prevention of RCD is urgent to the nerve tissues because the regeneration of nerve tissues and their functions are very hard. Several key types of RCD have been identified based on distinct cell death signaling pathways, such as apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis, in recent decades. Individually or in combination, these new types of RCD individually contribute to various pathological processes.
In this regard, the ability to target RCD is a viable approach for developing therapeutic strategies (including pharmaceutical discovery and stem cell-based therapy) for treating cancer and neurodegenerative diseases. For example, autophagy inhibitors such as inhibitors of 3-methyl-adenine or chloroquine were used in combination with anticancer drugs to suppress tumor cell survival by inhibiting autophagy. Drugs and compounds designed to promote RCD, on the other hand, have shown promising therapeutic effects. Shikonin, a Chinese herbal medicine, for example, has been applied to treat primary and metastatic osteosarcomas by inducing RIPK1/3-dependent necroptosis.
We welcome submissions as Original Research and Review articles focus on the development of novel strategies to target cell death signaling in human disease and the investigation of the underlying mechanisms. This Research Topic may include, but is not limited to, the subtopics listed below:
• Development of drugs, compounds, and stem cell-based therapy for targeting RCD;
• Regulatory mechanisms of drugs, compounds, and stem cell-based therapy in targeting RCD;
• Drug resistance related to RCD in cancer;
• Side effects in RCD-related targeted therapies;
• Discovery of new types or mechanisms of RCD in cancer and neurodegenerative diseases.